CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 427 enrolled
Drug / intervention
Adalimumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02750800
NCT02750800N/ACompleted
CompareCT.gov

Post-marketing Observational Study to Evaluate the Effect of HUMIRA (Adalimumab) Treatment With AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary in a Real-life Setting: VALUE

AbbVie·observational·Posted Apr 26, 2016·Updated Nov 6, 2019

In Brief

An observational study evaluating Adalimumab and AbbVie Care 2.0 for Rheumatoid Arthritis and 5 related conditions. Completed, enrolled 427 participants.

Detailed Summary

The objective of this post-marketing observational study (PMOS) was to evaluate the effectiveness of adalimumab plus the AbbVie Care 2.0 patient support program in participants with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis (Ps), Crohn's disease (CD) or ulcerative colitis (UC) in the routine clinical setting in Hungary.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 26, 2016
Enrollment StartApr 7, 2016
Primary CompletionApr 3, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.2 years ago

Interventions

Adalimumabbiological

Pre-filled syringe or pen, administered by subcutaneous injection

AbbVie Care 2.0behavioral

Supportive services provided to participants included reminder calls, emails, text messages, nursing services, dietician, and psychological support. An adalimumab starter pack, injection guide, digital and print educational materials were also provided.